94 related articles for article (PubMed ID: 3178236)
1. [Drug resistant mechanisms of platinum derivatives in a human cisplatin resistant ovarian cancer cell line].
Nishiya I; Yoshizumi N; Fujiwara J; Kagabu T
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2871-81. PubMed ID: 3178236
[TBL] [Abstract][Full Text] [Related]
2. [Cancer chemo-endocrine therapy and its cell biological basis].
Nishiya I
Hum Cell; 1998 Sep; 11(3):109-14. PubMed ID: 10086273
[TBL] [Abstract][Full Text] [Related]
3. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
5. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of a cisplatin-resistant human ovarian cancer cell line and the mechanism of resistance].
Kikuchi Y; Iwano I; Miyauchi M; Kita T; Kizawa I; Oomori K; Kato K
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Mar; 40(3):379-83. PubMed ID: 3361190
[TBL] [Abstract][Full Text] [Related]
7. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
8. [Reduced cisplatin-uptake by cisplatin-resistant human ovarian cancer cells].
Kikuchi Y; Iwano I; Miyauchi M
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2895-8. PubMed ID: 3178239
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression.
Jain D; Patel N; Shelton M; Basu A; Roque R; Siede W
Cancer Chemother Pharmacol; 2010 Oct; 66(5):945-52. PubMed ID: 20101404
[TBL] [Abstract][Full Text] [Related]
10. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
11. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
[TBL] [Abstract][Full Text] [Related]
12. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
Mueller S; Schittenhelm M; Honecker F; Malenke E; Lauber K; Wesselborg S; Hartmann JT; Bokemeyer C; Mayer F
Int J Oncol; 2006 Aug; 29(2):471-9. PubMed ID: 16820891
[TBL] [Abstract][Full Text] [Related]
13. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
14. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
Johnson SW; Laub PB; Beesley JS; Ozols RF; Hamilton TC
Cancer Res; 1997 Mar; 57(5):850-6. PubMed ID: 9041185
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of caffeine on potentially lethal damage repair in cisplatin-treated human osteosarcoma cells.
Yasutake H; Tsuchiya H; Tomita K; Matsunaga T; Nikaido O; Mori T
Anticancer Res; 1995; 15(3):831-7. PubMed ID: 7645967
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
17. [Cytokinetic effects of carboplatin and cisplatin on a human ovarian cancer cell line].
Yoshizumi N; Fujiwara J; Yoshizaki A; Sato M; Sakai R; Nishiya I
Hum Cell; 1988 Sep; 1(3):301-7. PubMed ID: 2979207
[TBL] [Abstract][Full Text] [Related]
18. Demonstration of an S phase population of cells without DNA synthesis generated by cisplatin and pentoxifylline.
Perras JP; Ramos R; Sevin BU
Cytometry; 1993; 14(4):441-8. PubMed ID: 8513698
[TBL] [Abstract][Full Text] [Related]
19. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
20. [Cytokinetic effects of cisplatin on cisplatin-resistant ovarian cancer cell lines].
Sasa H; Kikuchi Y; Hisano A; Ishii K; Nagata I; Kawai T; Aida S; Sugita M; Sugishita T; Tenjin Y
Hum Cell; 1992 Dec; 5(4):384-91. PubMed ID: 1304801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
